Navigation Links
Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
Date:4/9/2008

SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in two ongoing Phase 2 clinical trials for the treatment of hormone-refractory prostate cancer and metastatic colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-lo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
4. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
8. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 1Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 2Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 1Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 1ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 3ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 4ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 5ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 6ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 7ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 8ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 9ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 10ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 11